Topics

Bioverativ Inc. & Sobi Company Profile

08:54 EST 21st January 2020 | BioPortfolio

Bioverativ (NASDAQ: BIVV) is a global biopharmaceutical company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class research, development and commercialization of innovative therapies. Launched in 2017 following separation from Biogen Inc., Bioverativ builds upon a strong heritage of scientific innovation and is committed to actively working with the blood disorders community. The company’s mission is to create progress for patients where they need it most and its hemophilia therapies when launched represented the first major advancements in hemophilia treatment in more than two decades. For more information, visit www.bioverativ.com or follow @bioverativ on Twitter.


News Articles [59 Associated News Articles listed on BioPortfolio]

Sobi to acquire Dova for $915m to broaden hematology franchise

Sobi is to buy Dova Pharmaceuticals for $915 million in a bid to grow Sobi’s hematology portfolio, with liver cancer and low blood platelet medication Doptelet at the centre. Doptelet remains on the...

Sobi Acquires Novimmune Rare Disease Drug Emapalumab and Related Assets

STOCKHOLM, June 12, 2019 /PRNewswire/ — Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) has signed an agreement to acquire, from Novimmune’s shareholders, a newly established compa...

Astra köper förtur av Sobi

Svenska Sobi säjer en prioriteringsrätt till Astrazeneca för drygt 900 miljoner kronor.

Miljardaffär för Sobi

Specialistläkemedelsbolaget Sobi köper amerikanska Dova Pharmaceuticals. Prislappen ligger på cirka 9 miljarder kronor.

Sobi to acquire emapalumab drug from Novimmune

Swedish Orphan Biovitrum (Sobi) has agreed to buy a newly established firm from Novimmune for a consideration of SEK4,897m ($517.9m)....Read More... The post Sobi to acquire emapalumab drug from Novim...

Sobi pays CHF515mm to buy newco housing Gamifant from Novimmune

One year after granting Swedish Orphan Biovitrum AB (Sobi) exclusive global rights to the interferon gamma antagonist emapalumab (which has since been approved as Gamifant), Novimmune SA has now creat...

Sobi acquire Novimmune in deal worth more than £400 million

Swedish rare disease specialist Sobi has agreed to buy Swiss firm Novimmune ion a deal worth more than £400 million. The deal will see Sobi gain access to world class R&D facilities in the area o...

Irish haemophilia A patients to get continued access to Sobi’s extended half-life factor replacement therapy

The Republic of Ireland’s Haemophilia Product Selection and Monitoring Advisory Board (HPSMAB) and Sobi United Kingdom and Republic of Ireland, have extended their contract for the supply of Sobi’...

Drugs and Medications [3 Associated Drugs and Medications listed on BioPortfolio]

Orfadin [swedish orphan biovitrum ab (publ)]

These highlights do not include all the information needed to use ORFADIN safely and effectively. See full prescribing information for ORFADIN. ORFADIN (nitisinone) capsules, for oral useORFADIN (niti...

Kepivance [swedish orphan biovitrum ab (publ)]

These highlights do not include all the information needed to use Kepivance safely and effectively. See full prescribing information for KEPIVANCE. KEPIVANCE (palifermin) for injection, for intravenou...

Orfadin [swedish orphan biovitrum ab (publ)]

These highlights do not include all the information needed to use ORFADIN safely and effectively. See full prescribing information for ORFADIN. ORFADIN (nitisinone) capsules, for oral useORFADIN (niti...

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

Storm warning: lung disease in systemic juvenile idiopathic arthritis.

Dr. Nigrovic's work was supported by the NIH grants R01 AR065538, AR075906, AR073201 and P30 AR070253, the Fundación Bechara and the Arbuckle Family Fund for Arthritis Research. PAN is the recipient ...

Clinical Trials [0 Results]

None

Companies [10 Associated Companies listed on BioPortfolio]

Bioverativ Inc. and Sobi

Bioverativ (NASDAQ: BIVV) is a global biopharmaceutical company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class re...

Bioverativ Inc. & Sobi

Bioverativ (NASDAQ: BIVV) is a global biopharmaceutical company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class re...

Swedish Orphan Biovitrum AB

Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the lives of rare disease patients and their families. Sobi have a diversi...

Bioverativ Inc.,

Bioverativ, a Sanofi company, is dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class research, development, and commer...

Bioverativ Inc.

Bioverativ (NASDAQ: BIVV) is a global biotechnology company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class resear...

More Information about "Bioverativ Inc. & Sobi" on BioPortfolio

We have published hundreds of Bioverativ Inc. & Sobi news stories on BioPortfolio along with dozens of Bioverativ Inc. & Sobi Clinical Trials and PubMed Articles about Bioverativ Inc. & Sobi for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Bioverativ Inc. & Sobi Companies in our database. You can also find out about relevant Bioverativ Inc. & Sobi Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks



Searches Linking to this Company Record